ClinicalTrials.gg
TerminatedNCT05549323Updated Feb 25, 2026

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

A Phase 1 interventional study of PF-07054894 and Placebo in Ulcerative Colitis, sponsored by Pfizer. Terminated at 17 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated due to business decision. The decision to terminate the trial was not based on any safety concerns associated with PF-07054894.

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Colitis, Ulcerative by Pfizer — 3 open to participants now, 7 under way, 2 of them phase 3. Colitis, Ulcerative · Pfizer.

Enrollment
19th of 24
44 · median 129
Started
2022
with 3 others
Phase 1
3 of 42
none open now
Registered
35th of 42
by date

Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 19th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 1, and was the 35th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 42 studies in Colitis, Ulcerative by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Colitis, Ulcerative by Pfizer, or all of them as a file.
02

Study summary

This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of moderate to severe (Part A) or mild to moderate (Part B) UC for ≥3 months prior to baseline.
  • Active disease beyond the rectum (>15 cm of active disease from the anal verge at the screening endoscopy).

Part A (moderate to severe): Must have a 5 to 9 score on the modified mayo score, including an endoscopy subscore of at least 2. Part B (mild to moderate): Participants with mMS of 4 to 6, ES of ≥2 and RB score of ≥1

  • Must have inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC.
  • Total body weight >40 kg (88.2 lb).

Exclusion criteria

Exclusion Criteria:

  • Presence of indeterminate; microscopic; ischemic; infectious; radiation colitis; diverticular disease; Crohn's disease; colonic stricture; colonic obstruction/ resection; presence of cancer.
  • History of bowel surgery within 6 months prior to baseline.
  • History of significant trauma or major surgery within 4 weeks of screening or considered in imminent need of surgery or with elective surgery scheduled to occur during the study.
  • Presence of clinical signs of fulminant colitis or toxic megacolon, primary sclerosing cholangitis and evidence of colonic dysplasia, adenomas or neoplasia.
  • infections within 6 months of baseline
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Treatment Group 1

    Oral PF-07054894

    Drug: PF-07054894

  • Placebo comparator
    Treatment Group 2

    Matched Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Proportion of participants achieving clinical remission at Week 12 in participants with moderate to severe UC.

    Clinical remission based on modified Mayo Score is defined as endoscopic subscore equal 0 or 1 (without friability), stool frequency subscore equal 0 or 1, and rectal bleeding subscore equal 0

    Time frame: Week 12

  2. Part B: Percent change from baseline in the mMS in participants with mild to moderate UC.

    Time frame: Week 12

Secondary outcomes

  1. Part A: Proportion of participants achieving improvement in endoscopic appearance at Week 12

    Endoscopic improvement is defined as a Mayo endoscopic subscore of ≤1 (without friability)

    Time frame: Week 12

  2. Part A: Proportion of participants with clinical remission at Week 12

    Clinical Remission defined by Total Mayo Score ≤2 and no individual subscore \>1 and rectal bleeding subscore of 0

    Time frame: Week 12

  3. Part B: Proportion of participants achieving clinical remission at Week 12

    Clinical Remission based on modified Mayo Score is defined as endoscopic subscore 0 or 1 (without friability), stool frequency subscore 0 or 1, and rectal bleeding subscore 0.

    Time frame: Week 12

07

Study locations

17 sites
  • IHS Health Research
    Kissimmee, Florida 34741, United States
  • Kissimmee Endosocpy Center ( Endoscopy Only )
    Kissimmee, Florida 34741, United States
  • Orlando Diagnostic Center ( CXR Only )
    Kissimmee, Florida 34741, United States
  • Tampa Bay Endoscopy Center
    Tampa, Florida 33603, United States
  • GCP Clinical Research
    Tampa, Florida 33609, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Carta - Clinical Associates In Research Therapeutics Of America
    San Antonio, Texas 78212, United States
  • Charité Research Organisation
    Berlin, 10117, Germany
  • Charité Universitaetsmedizin Berlin - Campus Mitte
    Berlin, 10117, Germany
  • NZOZ Centrum Medyczne KERmed
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-231, Poland
  • SP ZOZ Szpital Uniwersytecki w Krakowie
    Krakow, Lesser Poland Voivodeship 30-688, Poland
  • Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś
    Warsaw, Masovian Voivodeship 04-501, Poland
  • KLIMED Marek Klimkiewicz
    Bialystok, Podlaskie Voivodeship 15-704, Poland
  • MZ Badania Slowik Zymla Spolka Jawna
    Knurów, Silesian Voivodeship 44-190, Poland
  • NZOZ Twoje Zdrowie EL Sp. z o. o.
    Elblag, Warmian-Masurian Voivodeship 82-300, Poland
  • Centrum Medyczne Med-Gastr
    Lodz, 91-034, Poland
  • IRMED
    Piotrkow Trybunalski, Łódź Voivodeship 97-300, Poland
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Nov 2025, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2022
First posted
Sep 22, 2022
StartActual
Nov 7, 2022
Primary completionActual
Nov 11, 2025
CompletionActual
Nov 11, 2025
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05549323
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 22, 2022
Start date
Nov 7, 2022
Primary completion
Nov 11, 2025
Completion
Nov 11, 2025
Last update
Feb 25, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-07054894

Start the discussion